INT11525

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1980
Last Reported 2011
Negated 1
Speculated 1
Reported most in Abstract
Documents 42
Total Number 43
Disease Relevance 6.91
Pain Relevance 18.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Vip)
Anatomy Link Frequency
muscle 4
nerves 4
MRF 2
bowel 2
small intestine 2
Vip (Rattus norvegicus)
Pain Link Frequency Relevance Heat
substance P 42 100.00 Very High Very High Very High
Somatostatin 40 100.00 Very High Very High Very High
qutenza 8 100.00 Very High Very High Very High
Serotonin 2 100.00 Very High Very High Very High
tetrodotoxin 36 99.98 Very High Very High Very High
Enkephalin 11 99.98 Very High Very High Very High
Endogenous opioid 1 99.92 Very High Very High Very High
agonist 33 99.88 Very High Very High Very High
gABA 26 99.84 Very High Very High Very High
cerebral cortex 18 99.76 Very High Very High Very High
Disease Link Frequency Relevance Heat
Vibrio Infection 5 100.00 Very High Very High Very High
Obesity 16 99.84 Very High Very High Very High
Diabetes Mellitus 18 99.70 Very High Very High Very High
Cancer 5 99.60 Very High Very High Very High
Functional Bowel Disorder 2 99.44 Very High Very High Very High
Diarrhoea 10 97.24 Very High Very High Very High
Congenital Anomalies 2 96.72 Very High Very High Very High
Irritable Bowel Syndrome /

Irritable Bowel Syndrome Super

7 96.40 Very High Very High Very High
Experimental Arthritis 6 90.72 High High
Rheumatoid Arthritis 16 85.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
NK-1 and NK-3-receptor agonists induced relaxation and stimulated vasoactive intestinal peptide (VIP) release and nitric oxide (NO) production: tetrodotoxin abolished VIP release, NO production, and relaxation, converting the response to NK-1-receptor agonists to contraction; the NO synthase inhibitor NG-nitro-L-arginine (L-NNA) abolished NO production, partly inhibited VIP release (56-64%, P < 0.01), and abolished relaxation; the VIP antagonist VIP-(10-28) partly inhibited NO production (73-74%, P < 0.001) and relaxation (56-58%, P < 0.01); and atropine augmented relaxation by 28-35% (P < 0.01).
Negative_regulation (inhibited) of Localization (release) of VIP associated with tetrodotoxin, antagonist and agonist
1) Confidence 0.49 Published 1993 Journal Am. J. Physiol. Section Abstract Doc Link 7682782 Disease Relevance 0 Pain Relevance 0.49
It was concluded that VIP was the neurotransmitter responsible for the dominant inhibitory neural input to intestinal circular muscle and that opioid peptides induce phasic contractions by suppressing VIP release.
Negative_regulation (suppressing) of Localization (release) of VIP in muscle associated with neurotransmitter and opioid
2) Confidence 0.43 Published 1987 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 3668852 Disease Relevance 0 Pain Relevance 0.84
Tetrodotoxin (5 x 10(-6) M) significantly--but incompletely--inhibited VIP release from control group animals at both intestinal sites.
Negative_regulation (inhibited) of Localization (release) of VIP associated with tetrodotoxin
3) Confidence 0.43 Published 1995 Journal Dig. Dis. Sci. Section Abstract Doc Link 7720477 Disease Relevance 0.73 Pain Relevance 0.10
Exposure to veratridine (3-100 microM) also induced concentration-dependent increases in VIP-LI release, an effect that was Ca(2+)-dependent and tetrodotoxin (TTX)-sensitive.
Negative_regulation (effect) of Localization (release) of VIP associated with tetrodotoxin
4) Confidence 0.41 Published 2001 Journal Neurochem. Int. Section Abstract Doc Link 11137631 Disease Relevance 0 Pain Relevance 0.13
Regulatory mechanism of electroacupuncture in irritable bowel syndrome: preventing MC activation and decreasing SP VIP secretion.
Negative_regulation (decreasing) of Localization (secretion) of VIP in bowel associated with spastic colon and electroacupuncture
5) Confidence 0.40 Published 2008 Journal Dig. Dis. Sci. Section Title Doc Link 17999187 Disease Relevance 0.35 Pain Relevance 0.45
Tetrodotoxin, hexamethonium and methionine enkephalin inhibited both the induced VIP release and the secretory response.
Negative_regulation (inhibited) of Localization (release) of VIP associated with tetrodotoxin and enkephalin
6) Confidence 0.39 Published 1990 Journal Acta Physiol. Scand. Section Abstract Doc Link 1972607 Disease Relevance 0.15 Pain Relevance 0.32
Somatostatin perfusion was shown to decrease VIP release, accompanied by increased contractions and amplification of responses to low-frequency electrical field stimulation.
Negative_regulation (decrease) of Localization (release) of VIP associated with somatostatin
7) Confidence 0.39 Published 1995 Journal Am. J. Physiol. Section Abstract Doc Link 7631789 Disease Relevance 0 Pain Relevance 0.27
[Postnatal lactotropic hypoactivity in rats: possible implication of VIP, endogenous opioids, dopamine and glucocorticoids].
Spec (possible) Negative_regulation (possible) of Localization (implication) of VIP associated with dopamine, narcan and endogenous opioid
8) Confidence 0.38 Published 1996 Journal Ann. Endocrinol. (Paris) Section Title Doc Link 8881293 Disease Relevance 0.23 Pain Relevance 0.44
In the isolated perfused canine ileal segment, exogenous motilin infused for 9 min, at concentrations from 10(-10) M and 10(-8) M, increased circular muscle motility concomitant with inhibiting tonic VIP release, maximum at 10(-8) M.
Negative_regulation (inhibiting) of Localization (release) of VIP in muscle
9) Confidence 0.38 Published 1991 Journal Peptides Section Abstract Doc Link 1800946 Disease Relevance 0 Pain Relevance 0.11
Naloxone increased, and Met-Enk decreased, vasoactive intestinal peptide (VIP) release during each component of the reflex.
Negative_regulation (decreased) of Localization (release) of vasoactive intestinal peptide associated with narcan
10) Confidence 0.38 Published 1987 Journal Am. J. Physiol. Section Abstract Doc Link 2887119 Disease Relevance 0 Pain Relevance 0.80
When tetrodotoxin (1 microM) was added to the incubation medium, the veratridine- and batrachotoxin-induced release of VIP was inhibited whereas K+-induced release was unaffected.
Negative_regulation (inhibited) of Localization (release) of VIP associated with tetrodotoxin
11) Confidence 0.38 Published 1982 Journal Neurosci. Lett. Section Abstract Doc Link 6123097 Disease Relevance 0 Pain Relevance 0.27
When the incubation medium did not contain any calcium, the action of potassium on the release of VIP was suppressed.
Negative_regulation (suppressed) of Localization (release) of VIP
12) Confidence 0.38 Published 1982 Journal Neurosci. Lett. Section Abstract Doc Link 6123097 Disease Relevance 0 Pain Relevance 0.27
In contrast, EA at Tianshu (ST-25) in combination with Tegaserod administration into the stomach can inhibit the secretion of VIP in rats with irritable bowel syndrome [8].
Negative_regulation (inhibit) of Localization (secretion) of VIP in stomach associated with spastic colon and electroacupuncture
13) Confidence 0.38 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2952296 Disease Relevance 1.08 Pain Relevance 0.93
Depletion of vasoactive intestinal peptide and substance P in parotid glands of atropinized rats during reflex secretion.
Negative_regulation (Depletion) of Localization (secretion) of intestinal peptide in parotid glands associated with qutenza and substance p
14) Confidence 0.38 Published 1996 Journal Exp. Physiol. Section Title Doc Link 8845143 Disease Relevance 0 Pain Relevance 0.50
DMPP-stimulated vasoactive intestinal peptide (VIP) release in dispersed ganglia was inhibited by [Met]enkephalin and bicuculline and augmented by naloxone and GABA, implying that inhibitory opioid and stimulatory GABA neurons regulate the activity of VIP interneurons.
Negative_regulation (inhibited) of Localization (release) of vasoactive intestinal peptide in neurons associated with gaba, narcan, enkephalin and opioid
15) Confidence 0.38 Published 1998 Journal Am. J. Physiol. Section Abstract Doc Link 9815026 Disease Relevance 0 Pain Relevance 0.80
These observations indicate that diabetes mellitus significantly diminishes VIP tissue concentrations and release from intestinal myenteric nerves.
Negative_regulation (diminishes) of Localization (release) of VIP in nerves associated with diabetes mellitus
16) Confidence 0.37 Published 1995 Journal Dig. Dis. Sci. Section Abstract Doc Link 7720477 Disease Relevance 0.72 Pain Relevance 0.09
Relaxation and VIP release were inhibited by tetrodotoxin and by the GABAA receptor antagonist bicuculline but not by the GABAB receptor antagonist phaclofen.
Negative_regulation (inhibited) of Localization (release) of VIP associated with tetrodotoxin and antagonist
17) Confidence 0.37 Published 1992 Journal Am. J. Physiol. Section Abstract Doc Link 1566850 Disease Relevance 0 Pain Relevance 0.55
However, while increase in release of ACh and ATP during nerve stimulation was suppressed in Ca2+-free medium and by the addition of the Ca2+ channel blocker cadmium, nerve-mediated VIP release was unaffected.
Neg (unaffected) Negative_regulation (unaffected) of Localization (release) of VIP in nerve
18) Confidence 0.37 Published 1987 Journal Regul. Pept. Section Abstract Doc Link 3685456 Disease Relevance 0 Pain Relevance 0.13
Tetrodotoxin and hexamethonium, but not atropine, inhibited oxytocin-stimulted release of VIP by 80% and 60% respectively.
Negative_regulation (inhibited) of Localization (release) of VIP associated with tetrodotoxin
19) Confidence 0.37 Published 1980 Journal Gastroenterology Section Abstract Doc Link 7439634 Disease Relevance 0 Pain Relevance 0.13
NK-2-receptor agonists elicited only contraction that was not affected by tetrodotoxin; these agonists also inhibited VIP release, NO production, and relaxation induced by NK-1- and NK-3-receptor agonists.
Negative_regulation (inhibited) of Localization (release) of VIP associated with tetrodotoxin and agonist
20) Confidence 0.36 Published 1993 Journal Am. J. Physiol. Section Abstract Doc Link 7682782 Disease Relevance 0 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox